Recently, support the prophylactic treatment of patients with pre- exposure to HIV (PrEP) increased substantially.
The CDC entities (Centers for Disease Control and Prevention, the US federal government) and WHO (World Health-Organization WHO) reinforce this support, as well as the Governor of New York State - Cuomo, who recently announced a plan with several fronts of actions to reduce rates of new infections in 75% for before 2020.
However, the role of prep contention has been the subject of heated debate - who should lead it; who should finance it; and whether it will work in a certain social level of the population. Its annual cost is about ten thousand dollars for health insurers, and this requires daily accessions to them for maximum profit, and involves periodic testing to monitor the situation of patients with HIV.
There is also concern about whether PrEP efficiency can be affected by two behavioral phenomena commonly observed in health promotion, self-selection and risk compensation.
Self-selection is, in this case, when those most at risk (based on behavior) do not understand, do not accept and are less likely to seek a drug. Self-selection is usually seen in health-promotion programs where those who need an intervention are often the most difficult to alcançar- but this can be overcome by reducing the stigma of HIV testing and treatment, potentially through financial incentives for HIV testing or adherence to medications.
The risk compensation occurs when those who agree to undertake preventive measures are taking more dangerous behavior because of a greater sense of protection. Although the risk of compensation has not been observed in the reference study iPrEx (prophylactic initiative of pre - exposure.
It is the third phase of clinical tests to determine if retroviral drug tenofovir / emtricitabine disoproxil fumarate- commercially known as Truvada could safely and efficiently prevent HIV infection men who are sexually related to man), it is potentially dangerous.
Parallel studies can be drawn from the experience of those who are taking statins (used to combat a high bad cholesterol ratio, as well as atherosclerosis), with still poorer diet and body weight gain.
This article was originally written by Mark J. Harris for the Vitality Institute in August of 2014 and was republished here under authorization. The original publication can be viewed on the Vitality Institute's blog at http://thevitalityinstitute.org/are-we-prepared-to-eradicate-hiv/. To learn more about Vitality Institute, visit:http://thevitalityinstitute.org/blog/
To read more of Mark texts, go to:http://markmdmph.wordpress.com/.
Translation: Márcio Catanho - Bachelor of Arts / translator and reviewer.
Contacts: firstname.lastname@example.org. 085- 88797627.